Ftse Mib
38.655,30
1,73%
DAX
22.986,82
2,01%
S&P 500
5.638,94
2,13%
NASDAQ
17.754,09
2,61%
Bitcoin
84.315,60
-0,04%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vaxcyte Inc (PCVX) Vaxcyte Inc (PCVX) Notizie

PCVX

Vaxcyte (PCVX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCVX
DataOraFonteTitoloSimboloCompagnia
07/03/202522:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCVXVaxcyte Inc
05/03/202522:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCVXVaxcyte Inc
25/02/202522:42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PCVXVaxcyte Inc
25/02/202522:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PCVXVaxcyte Inc
25/02/202522:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCVXVaxcyte Inc
25/02/202522:01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
12/02/202522:05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025NASDAQ:PCVXVaxcyte Inc
05/02/202514:00GlobeNewswire Inc.Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsNASDAQ:PCVXVaxcyte Inc
30/01/202522:05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim SMID Cap Biotech ConferenceNASDAQ:PCVXVaxcyte Inc
07/01/202507:13PR Newswire (US)Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmNASDAQ:PCVXVaxcyte Inc
03/12/202414:00GlobeNewswire Inc.Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsNASDAQ:PCVXVaxcyte Inc
12/11/202413:30GlobeNewswire Inc.Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsNASDAQ:PCVXVaxcyte Inc
05/11/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCVXVaxcyte Inc
05/11/202422:01GlobeNewswire Inc.Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
11/09/202422:05GlobeNewswire Inc.Vaxcyte to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
06/09/202422:05GlobeNewswire Inc.Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
05/09/202423:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCVXVaxcyte Inc
05/09/202405:58GlobeNewswire Inc.Vaxcyte Announces Pricing of $1.3 Billion Public OfferingNASDAQ:PCVXVaxcyte Inc
03/09/202422:01GlobeNewswire Inc.Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:PCVXVaxcyte Inc
03/09/202413:07GlobeNewswire Inc.Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
03/09/202400:40GlobeNewswire Inc.Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and OlderNASDAQ:PCVXVaxcyte Inc
06/08/202422:05GlobeNewswire Inc.Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
24/05/202423:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PCVXVaxcyte Inc
08/05/202422:05GlobeNewswire Inc.Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
02/04/202422:05GlobeNewswire Inc.Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCVXVaxcyte Inc
04/03/202414:30GlobeNewswire Inc.Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsNASDAQ:PCVXVaxcyte Inc
27/02/202422:01GlobeNewswire Inc.Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PCVXVaxcyte Inc
15/02/202422:05GlobeNewswire Inc.Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:PCVXVaxcyte Inc
03/02/202400:39GlobeNewswire Inc.Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:PCVXVaxcyte Inc
01/02/202422:05GlobeNewswire Inc.Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:PCVXVaxcyte Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCVX

La tua Cronologia

NYSE
EOG
EOG Resources
EU
BQPDL
Banque Postale Home Loan...
GATE
KAPUSDT
Kapital DAO Token
BOV
SBFG3R
Grupo SBF ON
BOV
SCAR3R
SÃO CARLOS ON
NASDAQ
ABNOWXX
Bank of Montreal Capped ...
NASDAQ
ABKOHXX
Bofa Finance Llc Issuer ...
NASDAQ
FCLNX
Beutel Goodman Total Wor...
EU
BNPGN
BNP Paribas 2.525% 23jan...
AMEX
SOLR
SmartETFs Sustainable En...
NASDAQ
ABLPJXX
Bank of Montreal Autocal...
BOV
MXRF12
Maxi Renda Fundo Invest ...
NYSE
FTK
Flotek Industries
BOV
ELET6T
ELETROBRAS
GATE
TARABTC
Taraxa Coin
AQSE
EQQU.GB
Invesco EQQQ Nasdaq100 U...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci